Spotlight: New name, but same old problems for Posimir

FDA headquarters, Silver Spring, MD

Durect ($DRRX) may have changed the name of its post-pain gall bladder surgery drug from "Posidur" to "Posimir" this year, but this has not stopped its run of back luck as the FDA has told the Cupertino, CA-based biotech that it must make a number of amendments to its ongoing Phase III Persist trial for the treatment. This includes adding the numbing agent bupivacaine as an active control, which it said in a statement it will now do. This will however add both time and money to complete the trial--but Durect said it believes that a positive outcome from this trial design "would result in a stronger NDA filing and potentially provide commercial advantages". The company is still on the look-out for potential partners for the drug, but this seems increasingly unlikely at this point, and comes after a series of disappointments. At an earnings call held by the company at the beginning of the year, the biotech said it decided to change the drug's name because of the concerns the FDA has had with Posidur. In 2014, the U.S. regulator told the biotech that investigators didn't provide sufficient data to prove that it could be safely administered and would need additional safety studies. This came two years after the program failed an efficacy test in a late-stage study. Its shares were down by 7.5% at 11:10 EDT. Release

@FierceBiotech: EuroBiotech Report: Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing. More | Follow @FierceBiotech

@JohnCFierce: FDA reviewers question efficacy, raise safety issues and cite a challenge on Clovis's rociletinib. Article | Follow @JohnCFierce


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

> Alder BioPharmaceuticals raised $125 million in a private offering. Release

> The hedge fund Starboard Value has built up a 9.8% stake in Depomed and now plans to fight for some board seats. Story

Medical Device News

@FierceMedDev: IBM and Pfizer join forces for real-time patient monitoring system for Parkinson's. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: FDA nitpicks Shionogi's head lice copay voucher over 'false and misleading' claims. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Theranos bolsters scientific board after independent technology review. Report

> Jury clears Abbott in $1B+ false claims trial over off-label uses of bile duct stents. News

> Abiomed gets FDA nod for expanded use of its Impella heart pump. Story

Pharma News

@FiercePharma:  Taiwan research head apologizes as he admits selling off OBI Pharma shares. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Unable to find a buyer, Sun will close the Ranbaxy plant in Ireland, lay off 70 remaining workers. Article | Follow @EricPFierce

@CarlyHFierce:  Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess. FiercePharmaMarketing article | Follow @CarlyHFierce

> Buyers eye Relypsa and its hyperkalemia drug. Article

> Hedge fund aims to oust Depomed board for 'troubling record.' Story

> Novo makes inroads in Japan with long-acting insulin Tresiba. News

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.